The Experts below are selected from a list of 18735 Experts worldwide ranked by ideXlab platform

Jonathan G Crowston - One of the best experts on this subject based on the ideXlab platform.

  • t lymphoCyte mediated lysis of MitomyCin C treated tenon s Capsule fibroblasts
    British Journal of Ophthalmology, 2004
    Co-Authors: Jonathan G Crowston, Julie T Daniels, Peng T Khaw, Lpy Chang, Arne N Akbar
    Abstract:

    Aims: To evaluate the effeCt of T Cell Co-Culture on MitomyCin C treated and untreated Tenon’s Capsule fibroblasts. Methods: IL-2 dependent allogeneiC T Cells were inCubated over a monolayer of MitomyCin C treated or Control fibroblasts. Fibroblast numbers were evaluated by direCt Counts using phase Contrast miCrosCopy. To determine whether T Cell mediated lysis was a ConsequenCe of MHC mismatCh, Co-Culture experiments were repeated with autologous T Cells. The effeCt of Fas reCeptor bloCkade was established by Co-inCubation with a Fas bloCking (M3) antibody. Results: T Cell Co-Culture resulted in a dramatiC reduCtion in fibroblast survival Compared to MitomyCin C treatment alone (p = 0.032). T Cell killing required fibroblast/lymphoCyte Cell to Cell ContaCt and was observed in both allogeneiC and autologous Co-Culture experiments. Fas bloCking antibodies did not signifiCantly inhibit T Cell killing (p = 0.39). ConClusion: T Cells augment MitomyCin C treated fibroblast death in vitro. Similar meChanisms may Contribute to the CytotoxiC effeCt of MitomyCin C in vivo and aCCount for the largely hypoCellular drainage blebs that are observed CliniCally.

  • apoptosis gene expression and death reCeptor signaling in MitomyCin C treated human tenon Capsule fibroblasts
    Investigative Ophthalmology & Visual Science, 2002
    Co-Authors: Jonathan G Crowston, Lydia H Chang, P H Constable, Julie T Daniels, Arne N Akbar, Peng T Khaw
    Abstract:

    PURPOSE. To examine the effeCt of MitomyCin-C on the expression of apoptosis genes in human Tenon Capsule fibroblasts and to evaluate whether death reCeptor signaling modulates MitomyCin-C CytotoxiCity.METHODS. BCl-2, Bax, BCl-x, Fas (CD95) and tumor neCrosis faCtor (TNF) reCeptor expression was determined by flow Cytometry in Control and MitomyCin-C-treated Tenon fibroblasts. Fibroblast death was quantified using a laCtate dehydrogenase release assay. The effeCt of Fas and TNF-reCeptor signaling was evaluated using Fas-speCifiC antibodies and soluble TNF-alpha.RESULTS. Tenon fibroblasts Constitutively express BCl-2, Bax, and BCl-x in Culture. MitomyCin-C (0.4 mg/mL) induCed a small but Consistent inCrease in the expression of all three proteins. Tenon fibroblasts express low levels of Fas but are resistant to the effeCts of Fas-reCeptor ligation. MitomyCin-C (0.01-1.0 mg/ mL led to a signifiCant inCrease in Fas expression at all ConCentrations tested (P < 0.01). Pretreatment with MitomyCin-C (0.4 mg/mQ rendered fibroblasts susCeptible to agonistiC anti-Fas monoClonal IgM antibodies (50-500 ng/mL and led to a further 50% reduCtion in viable fibroblasts at 48 hours, Compared with MitomyCin-C alone (P 0.<05). Antibodies that bloCk the Fas reCeptor did not inhibit MitomyCin-C-induCed apoptosis.CONCLUSIONS. MitomyCin-C alters apoptosis gene expression and primes fibroblasts to the effeCts of Fas reCeptor ligation. FaCtors other than the level of Fas reCeptor expression modulate the response to Fas reCeptor signaling. Determining the signals that regulate fibroblast apoptosis may help to reline therapeutiC strategies for switChing off the subConjunCtival healing response and maintaining intraoCular pressure Control.

E Assia - One of the best experts on this subject based on the ideXlab platform.

  • Combined MitomyCin C appliCation and free flap ConjunCtival autograft in pterygium surgery
    Cornea, 2004
    Co-Authors: F Segey, S Jaegerroshu, N Gefencami, E Assia
    Abstract:

    Purpose: To evaluate the long-term postoperative outCome and CompliCation rate of Combined intraoperative low-dose MitomyCin C appliCation and free ConjunCtival autograft for the treatment of pterygium. Methods: In a prospeCtive, ConseCutive, nonComparative Case series, a series of 46 ConseCutive patients (50 eyes) with primary pterygium (43 eyes) or reCurrent pterygium (7 eyes) were studied. The patients' ages ranged from 23.0 to 80.0 years (mean, 53.4 years). All patients underwent pterygium exCision Combined with intraoperative low-dose MitomyCin C appliCation (0.02% for 2 minutes) and free ConjunCtival autograft. The mean follow-up period was 29.2 months (range 12 to 41 months). The main outCome measures were reCurrenCe of pterygium and postoperative CompliCations. Results: Pterygium reCurred to a small extent (0.5 mm) in one eye (2%) of a patient with reCurrent pterygium. There were no intraoperative CompliCations. SubConjunCtival graft hematoma appeared soon after surgery and resolved spontaneously in five eyes (10%). One eye developed transient high intraoCular pressure without optiC nerve or visual field defeCt, and one eye developed mild symblepharon. There were no sight-threatening CompliCations or serious side effeCts. ConClusions: By applying a single low dose of MitomyCin C Combined with free ConjunCtival autograft during pterygium exCision, the reCurrenCe rate of pterygium Can be markedly reduCed.

J L Menezo - One of the best experts on this subject based on the ideXlab platform.

  • prospeCtive trial of intraoperative MitomyCin C in the treatment of primary pterygium
    British Journal of Ophthalmology, 1995
    Co-Authors: J Canoparra, Manuel Diazllopis, Miguel J Maldonado, E Vila, J L Menezo
    Abstract:

    AIMS--A prospeCtive, randomised, double blind, plaCebo Controlled study of intraoperative MitomyCin C as adjunCtive treatment of primary pterygium was ConduCted. METHODS--A total of 66 eyes of 54 patients with primary pterygium were treated with exCision, with or without a single intraoperative appliCation of MitomyCin C (0.1 mg/ml for 5 minutes) to evaluate the effiCaCy and toxiCity of this adjunCtive treatment. The mean follow up was 14.1 months (range 12-23 months). RESULTS--Of the 36 eyes that underwent simple exCision, 14 (38.8%) exhibited reCurrenCes whereas only one of 30 eyes (3.33%) treated with exCision and intraoperative appliCation of MitomyCin C had reCurrenCe (p = 0.0006). Neither serious oCular CompliCations nor systemiC toxiCity were noted in the MitomyCin C treated group. CONCLUSION--Intraoperative MitomyCin C appears to be an effeCtive and safe adjunCtive treatment of primary pterygium.

Steven A Madreperla - One of the best experts on this subject based on the ideXlab platform.

  • topiCal MitomyCin C for the treatment of ConjunCtival and Corneal epithelial dysplasia and neoplasia
    American Journal of Ophthalmology, 1997
    Co-Authors: Matthew W Wilson, John L Hungerford, Sheena M George, Steven A Madreperla
    Abstract:

    Purpose To evaluate the effiCaCy of topiCal MitomyCin C in treating ConjunCtival and Corneal epithelial dysplasia and neoplasia. Methods Seven eyes of seven patients with ConjunCtival and Corneal epithelial dysplasia and neoplasia were treated with one drop of topiCal MitomyCin C 0.04% four times a day for 7 days in alternate weeks. The patients' Charts were reviewed retrospeCtively. Patients with either multiple reCurrenCes or extensive oCular surfaCe involvement were treated. In all eyes, the diagnosis of epithelial dysplasia or neoplasia was Confirmed by histopathology before the onset of therapy. Patients were examined at least every 14 days during treatment and examined at intervals after Completion of treatment. Results With topiCal MitomyCin C, six eyes of seven patients had Complete CliniCal regression of their ConjunCtival and Corneal epithelial dysplasia and neoplasia. One eye of one patient had partial CliniCal regression of ConjunCtival and Corneal epithelial dysplasia. Follow-up after Completion of topiCal MitomyCin C therapy and exCision of residual disease ranged from 2 to 16 months (mean, 9 months; SD, 4.3 months) and was without CliniCal sign of reCurrenCe. TopiCal MitomyCin C therapy was assoCiated with transitory oCular disComfort, ConjunCtival injeCtion, tearing, photophobia, and punCtate epithelial keratopathy. ConClusion In this small series of eyes, topiCal MitomyCin C was effeCtive as a treatment for ConjunCtival and Corneal epithelial dysplasia and neoplasia.

P R Bock - One of the best experts on this subject based on the ideXlab platform.

  • intravesiCal baCillus Calmette guerin versus MitomyCin C for superfiCial bladder CanCer a formal meta analysis of Comparative studies on reCurrenCe and toxiCity
    The Journal of Urology, 2003
    Co-Authors: Andreas Bohle, Dieter Jocham, P R Bock
    Abstract:

    Purpose: We Compare the therapeutiC effiCaCy and toxiCity of intravesiCal baCillus Calmette-Guerin (BCG) with MitomyCin C on reCurrenCe of stages Ta and T1 bladder CarCinoma.Materials and Methods: Combined published and unpublished data from Comparative studies on BCG versus MitomyCin C for superfiCial bladder CarCinoma Considering possible Confounding faCtors were analyzed. Odds ratio (OR) and its 95% CI were used as primary effeCt size estimate. ToxiCity data were evaluated desCriptively.Results: In 11 eligible CliniCal trials 1,421 patients were treated with BCG and 1,328 were treated with MitomyCin C. Within the overall median followup time of 26 months 38.6% of the patients in the BCG group and 46.4% of those in the MitomyCin C group had tumor reCurrenCe. In 7 of 11 studies BCG was signifiCantly superior to MitomyCin C, in 3 studies no signifiCant differenCe was found, while in 1 study MitomyCin C was signifiCantly superior to BCG. An overall statistiCally signifiCant superiority of BCG versus mitomy...